{
  "docId": "019de076-f497-7249-9bc1-6e417e62b814",
  "docSlug": "fb4563ff56b082126dc8200b1dba24d8",
  "documentTitle": "BenevolentAI | Results Presentation Deck | 23 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 23,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "The slide uses a Gantt-style visualization to show the status of 5 specific drug development programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f497-7249-9bc1-6e417e62b814/11",
  "deckHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814",
  "deckJsonHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814.json",
  "deckAnchorHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.16
      },
      "kind": "list",
      "text": "The Company decided to focus on 5 high potential pipeline programmes in May at the strategic review following the decision to stop development of BEN-2293 for atopic dermatitis. All programmes were generated from the Benevolent Platform and are either First-in-Class or Best-in-Class. The Company has 10+ paused programmes that have the potential to enter the pipeline with regular re-evaluation undertaken.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34334e32-f19d-46a6-b0be-fd849112c339",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "table",
      "text": "Programme, Indication, Target, Chemistry & Lead Opt, Preclinical, Phase 1, Phase 2. BEN-8744, Ulcerative Colitis, PDE10, Phase 1 topline data readout: Q1 2024. BEN-28010, Glioblastoma Multiforme, CHK1, IND-ready: Q4 2023 - completed. BEN-34712, ALS, RARab, IND-ready: Q2 2024. Parkinson's Disease, Novel Target. Fibrosis, Novel Target.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60d3e760-a62b-4e2d-a716-58efc626aa43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Executing on pipeline progression post strategic review",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2487ec13-0c2b-45d1-b890-b955e2267251",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "4ef1edea-b4e2-4582-b0df-436290aa8347",
      "evidence": "The table uses horizontal bars to represent the status and progression of pipeline programs across development phases.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 16,
      "from": 8,
      "beatId": "f2ab71c9-53f6-440d-9d03-02e61c9ddb19",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Discussion of pipeline progression, strategic collaborations, and financial highlights",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 23,
      "from": 1,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "b0e19ace-ba0d-475a-81b8-bb29008de35f",
      "evidence": "The deck's overall narrative and key takeaways",
      "position": 1,
      "objective": "Communicating the why, how, and what of BenevolentAI's AI-driven drug discovery",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}